Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis - Takeaways - MDSpire

Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis

  • By

  • Qianqian Wu

  • Yifan Wang

  • Ting Zhao

  • Jie Guo

  • Xiaomin Zhang

  • Yang Tu

  • Feng Wang

  • June 22, 2026

  • 0 min

Share

  • 1

    The study investigated blood pressure changes associated with IL-17A inhibition in 50 patients with axial spondyloarthritis.

  • 2

    Patients received Ixekizumab, with significant improvements in disease activity and inflammatory markers observed.

  • 3

    Systolic and diastolic blood pressure showed time-dependent decreases, with reductions of 4.80 mmHg and 5.10 mmHg after 12 weeks.

  • 4

    The decline in diastolic blood pressure was more pronounced in patients with baseline hypertension.

  • 5

    No significant side effects were noted in hematological, hepatic, or renal function tests during the study.

Original Source(s)

Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis

  • by Qianqian Wu, Yifan Wang, Ting Zhao, Jie Guo, Xiaomin Zhang, Yang Tu, Feng Wang

  • June 22, 2026

Related Content

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

Every step counts and more steps count more for cardiovascular event prevention in hypertension

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.